EYPT
EyePoint Pharmaceuticals, Inc.
There isn't enough reported data to score EYPT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EYPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
EYPT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EYPT PE Valuation
EYPT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EYPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Moderate | |
| Low |
Analysts expect EYPT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EYPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.97 | -$0.97 |
| Q2 2026 | -$3.75 | -$1.06 |
| Q1 2026 | -$3.51 | -$1.09 |
| Q4 2025 | -$3.17 | -$0.85 |
| Q3 2025 | -$3.00 | -$1.01 |
| Q2 2025 | -$2.69 | -$0.91 |
| Q1 2025 | -$2.42 | -$0.61 |
| Q4 2024 | -$2.32 | -$0.50 |
EYPT is still losing money, but less than at its worst: $3.97 per share over the past year, against $5.60 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over EYPT on earnings, with more consistent year-over-year improvement.
EYPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $756K | -22% |
| Q2 2026 | $507K | -90% |
| Q1 2026 | $696K | -97% |
| Q4 2025 | $620K | -95% |
| Q3 2025 | $966K | -91% |
| Q2 2025 | $5.3M | -44% |
| Q1 2025 | $24.5M | +109% |
| Q4 2024 | $11.6M | -17% |
EYPT's revenue has slid since its 2025 peak: $756,000 last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12814% | -6394 points |
| Q2 2026 | -19207% | -18040 points |
| Q1 2026 | -12532% | -12333 points |
| Q4 2025 | -11346% | -10956 points |
| Q3 2025 | -6421% | -6110 points |
| Q2 2025 | -1167% | -802 points |
| Q1 2025 | -200% | +86 points |
| Q4 2024 | -390% | -274 points |
EYPT's operating margin was −12814% last quarter, down 6394 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EYPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over EYPT on profitability, with a higher operating margin.
EYPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | -$27.9M |
| Q2 2026 | -$63.5M | +$261K |
| Q1 2026 | -$81.5M | -$28.2M |
| Q4 2025 | -$66M | -$29.8M |
| Q3 2025 | -$60.2M | -$19.6M |
| Q2 2025 | -$63.8M | -$42.7M |
| Q1 2025 | -$53.4M | -$21M |
| Q4 2024 | -$36.2M | -$12.2M |
EYPT has burned cash in almost every quarter: −$299M over the past year, against −$214M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EYPT on cash generation, producing positive trailing cash flow while its opponent burns cash.
EYPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +15.3M shares |
| 1 year | +86% | +32.2M shares |
| 3 years | +143% | +41M shares |
EYPT has 70M diluted shares, up 86% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EYPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EYPT Net Leverage
EYPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EYPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 0.1 | Oversold |
EYPT's weekly RSI is 23 (oversold) and its Stochastic is 0 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EYPT PE vs Healthcare Sector
EYPT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EYPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 83% below |
| 20 week MA | $6.61 | 95% below |
| 50 week MA | $11.3 | 97% below |
| 100 week MA | $10.3 | 97% below |
| 200 week MA | $10.8 | 97% below |
EYPT is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EYPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $4.99 | -67% |
| 2021 | $4.99 | $13.6 | +172% |
| 2022 | $13.6 | $2.89 | -79% |
| 2023 | $2.89 | $23.1 | +700% |
| 2024 | $23.1 | $7.20 | -69% |
| 2025 | $7.20 | $18.3 | +154% |
| 2026 YTD | $18.3 | $0.32 | -98% |
EYPT's yearly returns have swung widely, from +700% in 2023 to −79% in 2022. It's down 98% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EYPT on returns for 2026, with the stronger performance.